WilliamAbramovitsMD

Dermatology • Dallas, TX

Acne & Rosacea, Cosmetic Dermatology, Dermatologic Surgery, Pediatric Dermatology

Owner, Investigator - DERMATOLOGY TREATMENT & RESEARCH CENTER

Join to view full profile

Dr. Abramovits is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abramovits' full profile

Already have an account?

Office
5310 Harvest Hill Rd
#160
Dallas, TX 75230
Phone+1 972-661-2729

Fax+1 972-661-0227

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1977 - 1979
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1976 - 1977
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1974 - 1975
University of Texas Health Science Center at HoustonInternship, Transitional Year, 1973 - 1974
Central University of VenezuelaClass of 1972

Certifications & Licensure

TX State Medical License 1989 - 2025
OK State Medical License 1976 - 1990
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Compulink Advantage EHR, Compulink, 2012

Clinical Trials

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis Start of enrollment: 2007 Feb 01
Completed
Phase 2
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Start of enrollment: 2010 Apr 01
Completed
Phase 2
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2010 Aug 01
Completed
Phase 2
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 May 01
Completed
Phase 3
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12
Active, not recruiting
Phase 3
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. Start of enrollment: 2020 Feb 03
Completed
Phase 3
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) Start of enrollment: 2021 May 04
Completed
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

113 citations
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2...
Neil A. Swanson, William Abramovits, Brian Berman, James H. Kulp, Darrell S. Rigel
Journal of the American Academy of Dermatology. 2010-04-01
8 citations
Hydrocortisone butyrate 0.1% cream (proprietary lipid rich cream vehicle) does not significantly suppress hypothalamic-pituitary-adrenal axis and is effective in pedia...
William Abramovits, Marcial Oquendo
Skinmed. 2010-05-01
26 citations
OPDIVO (Nivolumab).
Aditya K Gupta, Melissa A Macleod, William Abramovits
Skinmed. 2015-12-01

Journal Articles

Conceptual Issues in Dermatology and Medicine: Where Do Nonphysician Practitioners Rightfully Belong—a Dermatologist’s Perspective
William Abramovits, MD, ScienceDirect

Press Mentions

CommentaryJanuary 3rd, 2018

Other Languages

Spanish